{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:03Z","timestamp":1761901443941,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.msard.2019.01.015","type":"journal-article","created":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T05:43:31Z","timestamp":1546753411000},"page":"153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Interferon alpha might be an alternative therapeutic choice for refractory Neuro-Beh\u00e7et's disease"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3886-2813","authenticated-orcid":false,"given":"Ertugrul Cagri","family":"Bolek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Sari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2019.01.015_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s10067-004-0944-1","article-title":"Transverse myelitis in a patient with Behcet's disease: favorable outcome with a combination of interferon-alpha","volume":"24","author":"Calguneri","year":"2005","journal-title":"Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.msard.2019.01.015_bib0002","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","article-title":"Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease: an open study","volume":"62","author":"Calguneri","year":"2003","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.msard.2019.01.015_bib0003","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Behcet's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.msard.2019.01.015_bib0004","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ICU.0b013e3282f03d42","article-title":"Biologics in the treatment of uveitis","volume":"18","author":"Imrie","year":"2007","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.msard.2019.01.015_bib0005","first-page":"1051","volume":"47","author":"Kuemmerle-Deschner","year":"2008"},{"key":"10.1016\/j.msard.2019.01.015_bib0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.msard.2018.10.117","article-title":"Which treatment strategies for polyrefractory Neuro-Behcet disease?","volume":"27","author":"London","year":"2018","journal-title":"Multiple Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2019.01.015_bib0007","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/qjmed\/hcq125","article-title":"Interferon-alpha treatment for acute myelitis and intestinal involvement in severe Behcet's disease","volume":"103","author":"Monastirli","year":"2010","journal-title":"QJM : Mon. J. Assoc. Phys."},{"issue":"2","key":"10.1016\/j.msard.2019.01.015_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","article-title":"Interferon-alpha 2a treatment of neuro-Behcet disease","volume":"21","author":"Nichols","year":"2001","journal-title":"J. Neuroophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2019.01.015_bib0009","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00407749","article-title":"Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon","volume":"278","author":"Tsambaos","year":"1986","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.msard.2019.01.015_bib0010","first-page":"575","volume":"69","author":"Yang","year":"2008"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819300161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819300161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:52Z","timestamp":1761900232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819300161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":10,"alternative-id":["S2211034819300161"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.01.015","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon alpha might be an alternative therapeutic choice for refractory Neuro-Beh\u00e7et's disease","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}